Intellia Therapeutics reported further progress with two treatments that are now ensconced in Phase III of testing. Click ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest quarterly results and things are looking bullish. Revenues of US$17m beat estimates by a substantial 39% margin. Unfortunately, ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos” or the "Company”), today announced its 2025 first quarter business ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of ...

Analysts expect Intellia Therapeutics to report an earnings per share (EPS) of $-1.27. Anticipation surrounds Intellia ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Cathie Wood, the renowned investor and co-founder of Ark Invest, has made headlines again with her recent stock purchases. On Tuesday, Wood added to her stakes in Advanced Micro Devices (AMD), Shopify ...

Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The popular growth investor keeps adding to some of her favorite stocks.